Indian Biotechs Seek To Outsource Drug Marketing To MNCs
This article was originally published in PharmAsia News
Executive Summary
In somewhat of a trend reversal, some Indian biotechs are outsourcing their own drug projects as the drug-making business tightens. Avesthagen and Biocon have their own pipeline of drugs in development, but are discussing possible partnerships with multinational drug makers. Avesthagen has a nutritional molecule in clinical trials and seeks a MNC willing to market the drug while Avesthagen focuses on four other molecules in the pre-clinical stage. Biocon is in a similar situation with an insulin molecule just entering Phase III trials. (Click here for more
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.